# GSK announces positive results from DREAMM-8 phase III trial for Blenrep

- Link: https://www.directorstalkinterviews.com/__trashed-2/4121146435
- Published: 2024-03-07T07:20:06+00:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE) has announced positive headline results from an interim analysis of the
DREAMM-8 phase III head-to-head trial evaluating _Blenrep_ (belantamab mafodotin),
in combination with pomalidomide plus dexamethasone (PomDex), versus a standard 
of care, bortezomib plus PomDex, as a second line and later treatment for relapsed
or refractory multiple myeloma. The trial met its primary endpoint of progression-
free survival (PFS) at a pre-specified interim analysis and was unblinded early 
based on the recommendation by an Independent Data Monitoring Committee (IDMC).

·   Trial unblinded early at an interim analysis based on Independent Data Monitoring
Committee recommendation

·   _Blenrep_ (belantamab mafodotin) plus PomDex showed statistically significant
and clinically meaningful progression-free survival compared to bortezomib plus 
PomDex

·   Consistent efficacy results observed for _Blenrep_ combinations in two phase
III head-to-head trials

The belantamab mafodotin combination significantly extended the time to disease 
progression or death versus the standard of care combination. A positive overall
survival (OS) trend favouring the _Blenrep_ combination was also observed at the
time of this analysis. The trial continues to follow up for OS. The safety and tolerability
of the belantamab mafodotin regimen were broadly consistent with the known safety
profile of the individual agents.

> **Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said:**“
> The results seen in both DREAMM-7 and DREAMM-8 provide strong clinical evidence
> of the robust efficacy shown with belantamab mafodotin in use with standard of
> care combinations. We now look forward to discussing these data with regulators.
> If approved, we believe these combinations have the potential to redefine the 
> treatment of relapsed or refractory multiple myeloma and advance the standard 
> of care. This is exciting news for patients given the high unmet medical need 
> for both efficacious and easily administered therapies with differing mechanisms
> of action.”

DREAMM-8 is the second phase III head-to-head belantamab mafodotin combination trial
in second line and later treatment for multiple myeloma to report positive results.
Positive findings from DREAMM-7, a phase III head-to-head trial evaluating belantamab
mafodotin in combination with bortezomib and dexamethasone (BorDex) versus daratumumab
plus BorDex in the same treatment setting, were presented^(1) at the American Society
of Clinical Oncology (ASCO) Plenary Series on 6 February 2024. Detailed findings
from DREAMM-8 will be presented at a future medical congress and shared with regulatory
authorities.

_^(1) GSK press release issued 05 February 2024. DREAMM-7 phase III trial shows 
Blenrep combination nearly tripled median progression-free survival versus standard
of care combination in patients with relapsed/refractory multiple myeloma. Available
at: https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-
pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-
myeloma/._

Share on:
